

AD \_\_\_\_\_

GRANT NUMBER: DAMD17-94-J-4232

TITLE: Genetic Evidence of Early Breast Cancer

PRINCIPAL INVESTIGATOR: Darryl Shibata, M.D.

CONTRACTING ORGANIZATION: University of Southern California  
Los Angeles, California 90033

REPORT DATE: October 1995

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19960327 084

DTIC QUALITY INSPECTED 1

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE October 1995	3. REPORT TYPE AND DATES COVERED Annual 1 Oct 94 - 30 Sep 95		
4. TITLE AND SUBTITLE Genetics Evidence of Early Breast Cancer		5. FUNDING NUMBERS DAMD17-94-J-4232		
6. AUTHOR(S) Darryl Shibata, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Southern California Los Angeles, California 90033		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING/MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited		12b. DISTRIBUTION CODE		
13. ABSTRACT (Maximum 200 words)  The earliest phases of breast cancer are poorly characterized. A precise understanding of the genetic changes which herald incipient transformation would be invaluable for accurate early diagnosis and a better understanding of its pathogenesis. Towards this goal, we aim to identify clonal breast populations based on the detection of only one X-chromosome androgen receptor allele after differential methylation sensitive restriction enzyme digestion. Although this analysis is suitable for large amounts of DNA, it was not reliable when small cell numbers were analyzed. Since the earliest breast cancer lesions are small, we have yet to develop a suitable assay for their analysis. However, new efforts based on technical improvements show promise for both high sensitivity and reliability.				
14. SUBJECT TERMS BREAST CANCER, X-CHROMOSOME INACTIVATION, PATHOLOGY		15. NUMBER OF PAGES 9		
		16. PRICE CODE		
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

## GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet *optical scanning requirements*.

### Block 1. Agency Use Only (Leave blank).

**Block 2. Report Date.** Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

**Block 3. Type of Report and Dates Covered.** State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

**Block 4. Title and Subtitle.** A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

**Block 5. Funding Numbers.** To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C - Contract	PR - Project
G - Grant	TA - Task
PE - Program Element	WU - Work Unit Accession No.

**Block 6. Author(s).** Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

**Block 7. Performing Organization Name(s) and Address(es).** Self-explanatory.

**Block 8. Performing Organization Report Number.** Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

**Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es).** Self-explanatory.

**Block 10. Sponsoring/Monitoring Agency Report Number.** (If known)

**Block 11. Supplementary Notes.** Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

**Block 12a. Distribution/Availability Statement.** Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

**DOD** - See DoDD 5230.24, "Distribution Statements on Technical Documents."

**DOE** - See authorities.

**NASA** - See Handbook NHB 2200.2.

**NTIS** - Leave blank.

### Block 12b. Distribution Code.

**DOD** - Leave blank.

**DOE** - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

**NASA** - Leave blank.

**NTIS** - Leave blank.

**Block 13. Abstract.** Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

**Block 14. Subject Terms.** Keywords or phrases identifying major subjects in the report.

**Block 15. Number of Pages.** Enter the total number of pages.

**Block 16. Price Code.** Enter appropriate price code (*NTIS only*).

**Blocks 17. - 19. Security Classifications.** Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

**Block 20. Limitation of Abstract.** This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

       Where copyrighted material is quoted, permission has been obtained to use such material.

       Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

       Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

       In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

DS For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

DS In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

VS In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

       In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

  
\_\_\_\_\_  
PI - Signature                      10/25/95  
Date

TABLE OF CONTENTS

	PAGE
1) FRONT COVER	1
2) SF 298 PAGE	2
3) FOREWORD	3
4) TABLE OF CONTENTS	4
5) INTRODUCTION	5
6) BODY	5
7) CONCLUSIONS	9
8) REFERENCES	9

**TITLE: GENETIC EVIDENCE OF EARLY BREAST CANCER****INTRODUCTION:**

Cancer is thought to arise from a series of mutations which culminate in malignancy (1,2). The exact number, timing, and types of these mutations are unclear in breast cancer. Although the earliest genetic alterations in breast cancer are unknown, the earliest neoplastic lesions should be clonal. The goal of this proposal is to identify clonal regions of breast epithelium in order to further understand how early neoplasia arises. To accomplish this goal, we will analyze X-chromosome inactivation, since neoplastic regions should exhibit inactivation of the same X-chromosome whereas non-neoplastic regions should exhibit inactivation of both X-chromosomes.

Numerous studies have demonstrated that breast cancer is clonal based on X-chromosome inactivation studies (for example 3,4). This proposal seeks to extend these studies by analyzing both obvious tumor and the dysplastic, hyperplastic, and normal epithelium adjacent to the tumor. In this way, we seek to identify if the cancer arises from a generalized "field" of preneoplastic breast tissue. The normal and "pre-malignant" epithelium adjacent to primary tumors most likely includes some of the multi-step changes which precede transformation, and its analysis will help define the histologic characteristics and extent of this "field".

This topographic analysis requires the ability to microdissect at high resolution the thin layers of epithelium from surrounding stroma and tumor cells. The method for microdissection is selective ultraviolet radiation fractionation (SURF) (5). Small numbers (50-200) of cells (a single duct or lobule) with specific phenotypes (normal, pre-malignant, and tumor) (6) on a stained tissue section will be microscopically identified and covered with very small ink dots. UV radiation will then destroy everything except the DNA in the desired protected cells, and subsequent PCR should reveal their specific genotypes. X-chromosome inactivation provides the earliest evidence of clonal proliferation and can be used to identify clonal populations even if their underlying mutations are unknown (7,8). The topographical distributions of X-chromosome inactivation in the primary tumor, and its extension into adjacent non-neoplastic epithelium, can define the presence and extent of the altered epithelium which precedes transformation.

**BODY:**

Progress will be discussed in reference to the tasks identified in the proposal's statement of work:

**STATEMENT OF WORK: GENETIC PROFILE OF EARLY BREAST CANCER**

TASK 1: Optimize X-chromosome inactivation assay for SURF (Months 1-3)

A) Obtain female cell lines (N=4)

B) Make various mixtures of formalin fixed, paraffin embedded cell

lines

C) Compare results from SURF with DNA purified from cell lines

**TASK 2:** Determine the topographic distribution of X-chromosome inactivation in normal, premalignant, and malignant breast epithelium (Months 3-24)

A) Obtain fixed breast cancer specimens (40 per year)

B) Optimize X-chromosome analysis for PCR and SURF

C) Determine clonal patterns of X-chromosome inactivation in tumor tissue

D) Determine if the same clonal inactivation patterns extend into adjacent preneoplastic and normal epithelium

E) Analyze normal breast tissues

**Task 1:** We have obtained and isolated DNA from seven breast cancer cell lines (MCF-7, ER75, HEL1-8, BT474, MDAMB-453, MRF-7, MDA-BB) and have made artificial mixtures of known clonal compositions for analysis in Task 2.

**Task 2 A:** We have obtained formalin fixed tissue blocks from 40 breast cancer patients. They have been examined, and appropriate areas of tumor and adjacent normal tissue have been identified. The DNA has been extracted in bulk from the 40 breast cancers (both normal DNA and tumor DNA from the same patient).

**Task 2 B:** We have synthesized eight different PCR primers sets which span the methylation sensitive restriction enzyme sites (HpaII and HhaI) immediately 5' to the triplets CAG repeats androgen receptor located on the X-chromosome. The primary method needed for this study is the ability to distinguish between polymorphic methylated androgen receptor loci. Restriction digestion using methylation sensitive enzymes (HpaII, HhaI) will cut only the unmethylated allele. Subsequent PCR with primers located outside of the restriction sites should only amplify the methylated (ie uncut) allele. Therefore, clonal populations are identified by the amplification of only a single allele whereas polyclonal (reactive) populations would yield both alleles (9-11).

Using various sets of these PCR primers, we have identified 10 out of the 40 breast cancers from Task 1 which are well suited for further analysis since they are polymorphic for the number of CAG repeats, with their two different alleles easily distinguished on small acrylamide minigels. We have been able to demonstrate clonal X-chromosome inactivation using restriction enzyme digestion and PCR in these breast cancers, using bulk extracted DNA.

A major problem has been encountered when the assay is scaled down to analyze the small amounts of DNA present in microdissected regions. With small numbers of cells (less than 1,000), the assay becomes unreliable with polyclonal populations demonstrating clonal patterns and clonal populations demonstrating polyclonal patterns. This lack of reliability with small numbers of cells is a major problem since the primary goal of this proposal is the detection of small clonal populations.

The primary problem with the current approach appears to be the inability of PCR to accurately represent the proportion of alleles present in the original sample. Because small numbers of cells must be analyzed, a large number of PCR cycles (40-46) are necessary to achieve the necessary sensitivity. Unfortunately, if a minor residual fraction of one androgen receptor allele is present (still indicating a clonal population) the large number of PCR cycles obscures the true starting fraction, and both alleles are amplified to similar extents, leading to "false" negatives.

The contamination of clonal populations by the "unmethylated" allele is due to two sources. First, all breast cancers are contaminated by normal stroma cells. Even with microdissection, approximately 5-10% contamination by stroma cells is inevitable. Second, restriction digestion may be incomplete leading to a small fraction of uncut but unmethylated alleles. Therefore, clonal breast epithelial populations will always harbor a small fraction of contaminating "nonclonal" alleles.

Another problem is with polyclonal populations. Because formalin fixed, paraffin embedded tissues are used, DNA degradation is present. The extent of this degradation cannot be predicted and sometimes only a small number of molecules can be amplified. However, if only a small number of DNA molecules are suitable for PCR amplification, then the same allele may be selected by chance from even polyclonal populations. Therefore, using known reactive and monoclonal (ie tumor) tissues, reliable detection has not been possible.

To overcome these informative failures, we have changed the strategy. Although PCR can amplify small numbers of alleles to detectable levels, the primary problem is the inability of PCR to accurately represent the proportion of alleles present in the original sample. Therefore, we have altered the assay such that PCR is no longer used to distinguish between different allelic proportions. Instead, separation of the alleles occurs prior to PCR and PCR is only used to detect the alleles. This is illustrated below:

#### STRATEGY

- A) Isolate DNA from a small number of cells
- B) Cut with HpaII or HhaI
- C) Dilute to single copy (approximately 1 copy per PCR tube)
- D) PCR to detect single copy
- E) Gel analysis to identify allele based on size
- F) Count numbers of each allele


CLONAL= >70% or <30% of each allele  
POLYCLONAL= Each allele between 30-70%

#### ADVANTAGES:

- 1) Ability to "count" alleles avoids "false" positives due to analysis of too few alleles
- 2) Allows statistical analysis to identify clonal populations
- 3) Easily interpreted compared to bulk DNA analysis which requires judgment on whether a given PCR band is stronger than another.



## SMALL CELL POPULATIONS



**Task 2, C,D,E:** These tasks have not been accomplished as they are dependent on the success of Task 2B, as noted above.

#### CONCLUSIONS:

Although problems have been encountered, a new approach should provide the highly sensitive and reliable assay necessary to detect clonal breast epithelium. We feel the proposed assay is innovative and improves on prior methods to detect small clonal populations. Once this assay is optimized, investigations should proceed rapidly to identify early clonal breast epithelial populations.

#### REFERENCES:

1. Nowell PC: The clonal evolution of tumor cell populations. Science 194:23-28, 1976
2. Bishop JM: The molecular genetics of cancer. Science 245:305-11, 1991
3. Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Clonal analysis of fibroadenoma and phyllodes tumor of the breast. Cancer Res 1993;53:4071-74
4. Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. Clonal analysis of human breast cancer by means of the polymerase chain reaction. Cancer Res 1992;52:6594-97
5. Shibata D, Hawes D, Li ZH, Hernandez AM, Spruck CH, Nichols PW: Specific genetic analysis of microscopic tissue after selective ultraviolet radiation fractionation and the polymerase chain reaction. Amer J Pathol 141:539-43, 1992
6. Page DL, Simpson JF. Benign, high-risk, and premalignant lesions of the mamma. In, Bland KI, Copeland EM (eds) The Breast, WB Saunders Co, Philadelphia 1991, pp113-134
7. Fearon ER, Hamilton SR, Vogelstein B. Clonal analysis of human colorectal tumors. Science 1987;238:193-7.
8. Lyon MF. X-chromosome inactivation and developmental patterns in mammals. Biol Rev 1972;47:1-35
9. Tilly WD, Marcelli M, Wilson JD, McPhaul M. Characterization and expression of a cDNA encoding the human androgen receptor. PNAS 1989;86:327-31
10. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X-chromosome inactivation. Am J Hum Genet 1992;51:1229-39
11. Mashal RD, Lester SC, Sklar J. Clonal analysis by study of X chromosome inactivation in formalin-fixed paraffin-embedded tissue. Cancer Res 1993;53:4676-9